International Experience

Multi-Country Projects Lead by Pivotal

  • Adjuvant BC IIIA trial - FDA submission - 1056 patients = Spain/Germany/ Poland
  • Phases I/IIA PoC trials in:
    • Prostate cancer
    • Leukaemia, IIA - 70 patients - FDA submission = Spain/USA 
    • Cell Therapy Bladder Cancer, IIA  - 150 patients = Spain/Hungary/ France/Germany
    • Cell Therapy Perianal Complex Fistulae, IIIA - 214 patients = Spain/ UK/Germany/The Netherlands
    • Renal Carcinoma, IIIA - 40 patients = Spain/Portugal
    • CV Restenosis Prevention in stent patients, III - 60 patients = Spain/ Germany/Poland/Italy
    • Psoriasis, IIIB - 72 patients = Global
    • CABG, IIIA - 5700 patients = Global
    • Diabetes, IIIA - 1480 patients = Global
    • Systemic Sclerosis, II - 98 patients = Spain/UK/Germany/Poland/ Hungary
    • Acute and Complicated Cystitis, III - 580 patients = Spain/Greece
    • NSCLC, IIIA - 146 patients =  Spain/France/Italy

Countries Managed by Pivotal through local Partners

  • Portugal
  • France
  • Italy
  • UK
  • USA
  • Germany
  • Hungary
  • Poland
  • The Netherlands
  • Greece
  • Canada
Acciones de Documento